Contact
If you would like to learn more about Aggrastat®, get updates when they become available or have one of our product specialists contact you, please fill out the fields below.
If you would like to learn more about Aggrastat®, get updates when they become available or have one of our product specialists contact you, please fill out the fields below.
Indication:
Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Contraindications:
Warnings and Precautions:
Adverse Reactions:
For additional information, refer to the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.